Twist Bioscience (NASDAQ:TWST) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Twist Bioscience (NASDAQ:TWST) issued its earnings results on Monday. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09, Zacks reports. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. During the same period in the prior year, the firm earned ($0.75) earnings per share. Twist Bioscience’s revenue for the quarter was up 24.1% on a year-over-year basis. Twist Bioscience updated its Q2 2025 guidance to EPS and its FY 2025 guidance to EPS.

Twist Bioscience Trading Down 0.1 %

Shares of TWST opened at $51.99 on Wednesday. The stock has a 50 day moving average of $48.63 and a 200 day moving average of $46.21. Twist Bioscience has a 12 month low of $27.41 and a 12 month high of $60.90. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of -14.47 and a beta of 1.87.

Insider Buying and Selling at Twist Bioscience

In related news, COO Patrick John Finn sold 2,422 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $50.17, for a total value of $121,511.74. Following the transaction, the chief operating officer now owns 272,044 shares in the company, valued at approximately $13,648,447.48. This represents a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emily M. Leproust sold 7,968 shares of the firm’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $48.00, for a total value of $382,464.00. Following the completion of the sale, the chief executive officer now directly owns 581,584 shares of the company’s stock, valued at $27,916,032. This represents a 1.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 48,707 shares of company stock worth $2,343,623 in the last quarter. 3.01% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research analysts have weighed in on TWST shares. Leerink Partners upped their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird upped their target price on shares of Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday. Barclays dropped their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research report on Tuesday, November 19th. TD Cowen reissued a “buy” rating and set a $58.00 price objective on shares of Twist Bioscience in a report on Tuesday, November 26th. Finally, Scotiabank raised their target price on Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a report on Tuesday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $53.80.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.